Chiasma's oral ocreotide controls acromegaly in some patients
This article was originally published in Scrip
Chiasma is raising capital to fund a new drug application (NDA) submission to the US FDA for oral ocreotide in the treatment of acromegaly based on Phase III results that were published on 9 February in the Journal of Clinical Endocrinology and Metabolism (JCEM).
You may also be interested in...
With a near-term launch of Mycapssa unlikely, Chiasma cuts its commercial staff while it evaluates how to respond to an April complete response letter.
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.